A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC).

被引：1
|
作者：
Funt, Samuel Aaron
Jatwani, Karan
Makris, Michelle
Regazzi, Ashley Marie
Lee, Chung-Han
Teo, Min Yuen
McHugh, Deaglan Joseph
Mccoy, Asia S.
Hettich, Grace
Wong, Phillip
Abu-Akeel, Moshen
Wolchok, Jedd D.
Merghoub, Taha
Al-Ahmadie, Hikmat
Ostrovnaya, Irina
Chaim, Joshua
Durack, Jeremy C.
Iyer, Gopa
Bajorin, Dean F.
Rosenberg, Jonathan E.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Mt Sinai St Lukes & West Hosp, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4559
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and efficacy of first-line docetaxel-gemcitabine in metastatic breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 168 - 168
  • [32] First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma
    Naiki, Taku
    Nagai, Takashi
    Sugiyama, Yosuke
    Etani, Toshiki
    Nozaki, Satoshi
    Iida, Keitaro
    Noda, Yusuke
    Shimizu, Nobuhiko
    Isobe, Teruki
    Matsumoto, Daisuke
    Kubota, Hiroki
    Hamamoto, Shuzo
    Ando, Ryosuke
    Kawai, Noriyasu
    Yasui, Takahiro
    ONCOLOGY, 2021, 99 (10) : 622 - 631
  • [33] Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis.
    Giannatempo, Patrizia
    Pond, Gregory Russell
    Sonpavde, Guru
    Raggi, Daniele
    Galsky, Matt D.
    Naik, Gurudatta
    Nicolai, Nicola
    Salvioni, Roberto
    Procopio, Giuseppe
    De Braud, Filippo G.
    Necchi, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis
    Necchi, A.
    Giannatempo, P.
    Pond, G.
    Raggi, D.
    Nicolai, N.
    Salvioni, R.
    Procopio, G.
    De Braud, F.
    Sonpavde, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 55 - 56
  • [35] Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
    Liu, Xiaoyan
    Lang, Yitian
    Chai, Qingqing
    Lin, Yan
    Liao, Yahui
    Zhu, Yizhun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
    Li, Ying
    Wang, Lin Run
    Chen, Jian
    Lou, Yan
    Zhang, Guo Bing
    DISEASE MARKERS, 2014, 2014
  • [37] Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study
    Kim, Hyunho
    Lee, Seung-Hwan
    Kim, Dong Hwan
    Lee, Ji Youl
    Hong, Sung-Hoo
    Ha, U-Syn
    Kim, In-Ho
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (05) : 2113 - 2121
  • [38] Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.
    Rosenberg, Jonathan E.
    Gajate, Pablo
    Morales-Barrera, Rafael
    Lee, Jae-Lyun
    Necchi, Andrea
    Penel, Nicolas
    Zagonel, Vittorina
    Sierecki, Mitchell Robert
    Piciu, Ana-Maria
    Ellinghaus, Peter
    Sweis, Randy F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy
    Galsky, Matthew D.
    Moshier, Erin
    Krege, Susan
    Lin, Chia-Chi
    Hahn, Noah
    Ecke, Thorsten
    Sonpavde, Guru
    Pond, Gregory
    Godbold, James
    Oh, William K.
    Bamias, Aristotle
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 48.e1 - 48.e8
  • [40] IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
    Bellmunt, J.
    Balar, A.
    Galsky, M. D.
    Loriot, Y.
    Theodore, C.
    Grande Pulido, E.
    Castellano, D.
    Retz, M.
    Niegisch, G.
    Bracarda, S.
    Necchi, A.
    Vaishampayan, U.
    Sridhar, S.
    Eigl, B. J.
    Hussain, S.
    van der Heijden, M.
    Danner, B.
    Mariathasan, S.
    Legrand, F.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
12345